



Scottish Perinatal Network

National Neonatal Guidance

Hypoxic Respiratory Failure in Term & Near Term Infants

Disclaimer

This guidance is not intended to be interpreted or used as a standard of care. Standards of care are determined based on the full range of clinical information available for an individual case and may change as scientific knowledge, technology, and clinical practice evolve. Following the recommendations in this guidance does not guarantee a successful outcome in every situation, nor does it encompass all appropriate methods of care or exclude other acceptable approaches that may achieve the same results.

Clinical judgement remains the responsibility of the healthcare professional(s) involved in the patient's care. Clinicians must also be mindful of the requirements of patient autonomy and patient-centred care, which may involve a patient opting (after discussion of the available treatment options) for a treatment which is not the treatment recommended in the guidance. Where treatment involves deviation from national guidance, or local guidance derived from them, this should be fully documented in the patient's records at the time the decision is made.

Document Control Sheet

Title	Hypoxic Respiratory Failure in Term and Near Term Infants
Date Published/ Issued:	04/06/2026
Date Effective From:	08/01/2021
Version/Issue Number:	2.0
Document Type:	Guidance
Document Status:	Final
Owner:	Scottish Perinatal Network
Author:	See Development section
Approver:	Scottish Perinatal Network Neonatal Guideline Oversight Group
Review Date:	22/04/2029
Contact:	nss.perinatalnetwork@nhs.scot
IQM Reference:	NSD611-005.06

Revision History

Version	Date	Summary of Changes	Name
V1	08/01/2021	Final document – initial publication	
V1.1	22/04/2026	In stages 1, 2, and 3: Consider discontinuing iNO if no response; Dobutamine can be considered as an alternative to adrenaline; Avoid using dopamine; Aim for Mean Blood Pressure >45 mmHg & Pulse Pressure >20 mmHg. In stage 3: Consider targeted use of additional cardiotropes in experienced centres.	Dr Andrew McLaren Dr Mahmoud Montasser
V2	03/06/26	Update format. Applied 'Note' re. dosages to Stages 1, 2, 3 and Vasoactive Drugs Table. Updated images. Vasoactive drugs advisory added, (p26).	Roberta Shanks, Programme Support Officer, SPN Dr Mahmoud Montasser Dr Andrew MacLaren

Responsibilities for implementation

Organisational:	Chief Executive & Operational Management Team
Sector:	General Managers, Medical & Nursing Leads
Departmental:	Clinical Leads

Contents

Introduction.....	5
Principles of Treatment.....	6
Referral pathway for infants needing ECMO support.....	7
Stages	8
Stage 0 – In utero diagnosis.....	8
Stage 1	8
Stage 2.....	10
Stage 3.....	11
Neonatal ECMO	13
Introduction.....	13
Aim of Neonatal ECMO	13
Indications.....	13
Further Reading	14
Causes of Respiratory Failure in the Term Infant	14
Persistent Pulmonary Hypertension of the Newborn (PPHN)	14
Congenital Diaphragmatic Hernia (CDH).....	15
Meconium Aspiration Syndrome (MAS).....	15
Sepsis.....	15
Respiratory Distress Syndrome (RDS).....	15
Phenotypes of Acute Pulmonary Hypertension	16
Pathophysiology of hypoxic respiratory failure	16
Clinical Assessment and Monitoring.....	18
Management.....	19
Pulmonary vasodilator therapies	21
Management of Systemic Hypotension in HRF	22
Important considerations for Milrinone:.....	22
Special Considerations in Management of Hypotension and Cardiac Function in PPHN:.....	23
References	24
Development	24
Appendix 1.....	25
Vasoactive Drugs	26

Introduction

This guidance has been developed for clinical staff caring for term and near term (>34wk) infants throughout Scotland.

Respiratory failure is a failure of the respiratory system to oxygenate (hypoxaemia) or to clear CO₂ (hypercapnia). Invasively ventilated babies with one or more of:

- **Oxygen requirement $\geq 60\%$** (to achieve preductal saturation of 94% and above)
- **pCO₂ ≥ 8 kPa**
- **H⁺ ≥ 60 (pH <7.22)**

should be considered at risk of hypoxic respiratory failure (HRF) and persistent pulmonary hypertension of the newborn (PPHN). These babies require advanced management strategies and early discussion with a specialist centre for consideration of transfer.

The aim is to provide standardised care for these babies and provide a pathway to aid management and referral to a specialist centre if required for ongoing care. This guidance will not cover the management of babies born with congenital diaphragmatic hernia. These babies should follow the established pathways found at

<https://www.nn.nhs.scot/scans/professionals/sdhcn-guidelines/>.

For babies with associated hypoxic ischaemic encephalopathy, management of this should be as per the Scottish Cooling Group guidance on Therapeutic Hypothermia: [Neuroprotection-Care-Pathway-for-Infants-with-HIE-3rd-Edition-Oct-2025.pdf](#)

Principles of Treatment

1) Optimise lung recruitment and ventilation considerations:

- Select appropriate ETT size to minimise leak
- Optimise ventilator settings, avoid under-recruitment and over-distension.
- Consider use of High frequency oscillation if familiar with its use.
- Treat pneumothorax
- Keep airway clear of obstruction with suction where necessary
- Use surfactant if suspected surfactant deficiency/inactivation

2) Minimise pulmonary vascular resistance, optimise pulmonary blood flow:

- Minimise excessive noise and potentially disturbing bright light
- Optimise acid-base status
- Trial of pulmonary vasodilators e.g. inhaled nitric oxide.

3) Optimise cardiac function, systemic blood flow and oxygen delivery

- Treat hypovolaemia
- Consider use of inotropes to optimise ventricular function and blood pressure
- Optimise haemoglobin (target Hb > 120)
- Echocardiography if expertise available to assess function and rule out structural anomalies

4) Reduce oxygen consumption

- Use sedation and muscle relaxation
- Maintain normothermia

5) Treat possible associated conditions:

- e.g. sepsis, meconium aspiration, hypoxic ischaemic encephalopathy
- For babies with HIE, therapeutic hypothermia should be managed as per the Scottish National Cooling Group guidance. Therapeutic hypothermia is not a contraindication to ECMO.

More detailed information on the management of Hypoxic Respiratory Failure can be found in the '*Further Reading*' section of the guidance.

Referral pathway for infants needing ECMO support

Pathway for referral to Royal Hospital for Children, Glasgow

- For babies in a level 2 unit, initial discussions should be with their local level 3 unit.
- However, any baby where there is concern can be discussed with the on-call consultant at RHC Glasgow
- Baby fulfils criteria for ECMO (below) OR worsening respiratory failure:
- Contact RHC, Glasgow Receiving Neonatal Consultant on **0141 452 2114**.
- If transfer is thought to be required, call the **ScotSTAR Emergency Line on 03333 990 222** and request a conference call between:
 - Referring Unit
 - Receiving neonatal consultant at RHC, Glasgow
 - On-call ECMO surgeon (if thought to be required by receiving consultant)
 - ScotSTAR transport consultant
 - ScotSTAR transport team (clinician and nurse).
- In this way, advice can be given to the referring centre, a clear history and clinical status can be outlined and the decision to transfer can be carried out in a single call.

The monographs for each of the medications referenced in this pathway can be found locally or at <https://www.perinatalnetwork.nhs.scot/professionals/guidance/local-regional-drug-monographs/>.

Stages

Stage 0 – In utero diagnosis

Plan to deliver in a Level 3 NICU or ECMO centre for likely cases of severe respiratory failure.

This would include babies with:

- Severe congenital diaphragmatic hernia. See guidance for antenatal management of congenital diaphragmatic hernia: <https://www.nn.nhs.scot/scans/professionals/sdhcn-guidelines/>
- Suspected significant pulmonary hypoplasia of other cause.
 - *Consideration should be given to antenatal transfer of any mother presenting with a history of PPROM from <24 weeks, or PPROM with oligohydramnios from 24 – 30 weeks to a centre providing inhaled Nitric Oxide therapy.*

Stage 1

Immediate management of term or near-term babies with hypoxic respiratory failure (FiO₂>60%, pCO₂ > 8kPa) in first 1-2 hours of life.

Management of all term & near term infants with high FiO₂ worsening on non-invasive ventilation:

- Intubate & ventilate
- Start 1st line antibiotics (most commonly benzyl penicillin & gentamicin).
- Standard monitoring + Pre/post ductal saturations (difference >5% is significant)
- UVC (double-lumen)/ PICC (double-lumen)
- UAC/ peripheral arterial line
- Chest X-ray
- Commence intravenous fluids as per your local guidance. Ensure normoglycaemia

Note: Drug dosages are only guaranteed to be correct at the date of publication. Clinicians must verify against e.g. BNF for Children or current monographs in the event that these should change in the period between publication and review.

	ENSURE:	CONSIDER:
Respiratory	Ensure adequate ventilation • Intubate and commence mechanical ventilation • Avoid atelectasis • Avoid overdistension ('flattened' diaphragm and 'narrow' heart on CXR) • Exclude pneumothorax • Aim pCO₂ of 5 - 7 kPa • Avoid acidosis – aim for H⁺ <60, pH >7.2 • Aim pre-ductal SaO₂ >94%	Pulmonary Vasodilators • Start inhaled Nitric Oxide at 20ppm, if evidence of pulmonary hypertension (clinically or on Echo). Consider stopping if no response after discussion with receiving centre. • Surfactant • Surfactant 200mg/kg if evidence of surfactant deficiency/ inactivation • Remember 'DOPE' • Dislodgement of ETT • Obstruction • Pneumothorax • Equipment failure

	ENSURE:	CONSIDER:
Cardiovascular	Optimise intravascular volume 10ml/kg bolus 0.9% NaCl if suspicion of hypovolaemia (use packed red cells if suspicion of anaemia) - Aim to keep mean BP >45mmHg - Monitor for narrow pulse pressure which is an indication of myocardial dysfunction - Monitor urine output	Inotropes - Commence low dose Adrenaline at 0.03 - 0.05 mcg/kg/min OR* - Dobutamine 5-10 mcg/kg/min** * AVOID DOPAMINE USE **Dobutamine dose above 10mcg/kg/min should be avoided due to risk of tachycardia leading to reduced cardiac output with no additional benefits but more side effects.
Vascular Access	- UAC or peripheral arterial line - UVC or PICC	
Sedation/ Analgesia	Morphine 100mcg/kg bolus followed by infusion of 20mcg/kg/hr (titrate according to baby's response)	Muscle Relaxation - Vecuronium or Rocuronium Sedation - Midazolam 50-100mcg/kg bolus followed by infusion of 60-100 mcg/kg/hour, titrated to response
Exclude	Congenital cardiac disease by echocardiogram (if possible)	If congenital cardiac disease cannot be excluded commence prostaglandin E1 to maintain ductal patency (5-20 nanog/kg/min)
Monitoring	- Standard bedside monitoring - Pre and post ductal saturation	
Referral	If care is in a level 2 unit, discuss baby with local level 3 unit for advice and transfer.	

Stage 2

At 2-4 hours with baby continuing to need high oxygen requirement ($\text{FiO}_2 > 60\%$), has severe lung disease or clinical suspicion of HRF.

Note: Drug dosages are only guaranteed to be correct at the date of publication. Clinicians must verify against e.g. BNF for Children or current monographs in the event that these should change in the period between publication and review.

	ENSURE:	CONSIDER:
Respiratory	Ensure adequate ventilation - Avoid atelectasis - Avoid overdistension ('flattened' diaphragm and 'narrow' heart on CXR) - Exclude pneumothorax - Aim pCO_2 of 5 - 7 kPa - Avoid acidosis – Aim H^+ < 60, $\text{pH} > 7.2$ - Aim pre-ductal $\text{SaO}_2 > 90\%$ Specific pulmonary vasodilators - Start iNO at 20ppm if evidence of PHT. If no response, discontinue and discuss further with referral centre.	Surfactant - Surfactant 200mg/kg if evidence of surfactant deficiency/ inactivation clinically, on CXR or lung US. Ventilation - Consider HFOV if familiar with its use. Remember 'DOPE' - Dislodgement of ETT - ETT Obstruction - Pneumothorax - Equipment failure
Cardiovascular	- Further 10ml/kg NaCl bolus if evidence of hypovolaemia - Avoid multiple fluid boluses - Keep MBP > 45, ensure pulse pressure of > 20. If narrow pulse pressure < 20, consider inotropic support. Monitor urine output - Correct metabolic acidosis - Adrenaline 0.03-0.08mcg/kg/min OR Dobutamine 5-10 mcg/kg/min - Avoid tachycardia $> 180/\text{min}$	Fluids - Consider transfusion with 20ml/kg packed red blood cells to keep Hb > 120 Inotropes - Start IV hydrocortisone 1-2.5mg/kg QDS AVOID DOPAMINE USE
Vascular Access	- UAC or peripheral arterial line - Double lumen UVC or PICC	
Sedation/ Analgesia	- Morphine 100mcg/kg bolus followed by infusion of 20mcg/kg/hr (titrate according to baby's response) * - Vecuronium or Rocuronium	Midazolam 50-100mcg/kg bolus followed by infusion of 60-100 mcg/kg/hr* *Beware of hypotensive effect of sedation and muscle relaxation.
Exclude	Congenital cardiac disease by echocardiogram (if possible)	If congenital cardiac disease cannot be excluded commence prostaglandin E2 to maintain ductal patency (5-20 nanog/kg/min)
Monitoring	- Standard bedside monitoring - Pre and post ductal saturation - Advanced monitoring as in the education section	

	ENSURE:	CONSIDER:
Referral	If this is a level 2 unit, discuss baby with local level 3 unit, ScotSTAR AND RHC, Glasgow for advice and possible transfer (as outlined below).	

Stage 3

Continued worsening oxygen requirement or hypercarbia, has severe lung disease or clinical suspicion of PPHN

Note: Drug dosages are only guaranteed to be correct at the date of publication. Clinicians must verify against e.g. BNF for Children or current monographs in the event that these should change in the period between publication and review.

	ENSURE:	CONSIDER:
Respiratory	Ensure adequate ventilation • Trial of HFOV if familiar with its use. • Avoid atelectasis • Avoid overdistension ('flattened' diaphragm and 'narrow' heart on CXR) • Exclude pneumothorax • Aim pCO₂ of 5 - 7 kPa • Avoid acidosis – Aim H⁺ <60, pH >7.2 • Aim to keep pre-ductal SaO₂ >85% Specific pulmonary vasodilators • Start iNO at 20ppm if evidence of PHT. If no response, discontinue and discuss further with referral centre.	Remember 'DOPE' • Dislodgement of ETT • ETT Obstruction • Pneumothorax • Equipment failure Surfactant • Surfactant 200mg/kg if evidence of surfactant deficiency/ inactivation clinically, on CXR or lung US. Remember • Consider LV dysfunction or other phenotypes of pulmonary hypertension if no response to iNO therapy.
Cardiovascular	• Keep MBP >45, ensure pulse pressure of >20. If narrow pulse pressure <20, consider inotropic support. Monitor urine output • Monitor urine output • Adrenaline 0.03-0.1mcg/kg/min • OR Dobutamine 5-10 mcg/kg/min • Hydrocortisone 1-2.5mg/kg QDS • 20ml/kg Packed RBCs (if Hb <130) • Correct metabolic acidosis.	Inotropes • Consider targeted use of additional cardiotropes in experienced centres e.g. ○ Milrinone 0.3-0.7 mcg/kg/min ○ Noradrenaline 0.03-0.08 mcg/kg/min ○ Vasopressin 0.0003-0.0009 mcg/kg/min Remember • Avoid repeatedly increasing inotropic support without further discussion as high doses can lead to reduced cardiac output via chronotropy and vasoconstriction. • Beware of excess tachycardia as doses of catecholamines increase. This can have a negative inotropic effect.
Vascular Access	• UAC or peripheral arterial line • Central line for inotropes	

	ENSURE:	CONSIDER:
Sedation/ Analgesia	Sedation • Morphine 100mcg/kg bolus followed by infusion of 20mcg/kg/hr (titrate according to baby's response) • Midazolam 100mcg/kg bolus followed by infusion at 60-100mcg/kg/hr Muscle Relaxation • Vecuronium or Rocuronium	
Exclude	• Congenital heart disease	Commence prostaglandin E2 if CHD cannot be ruled out at 5-20 nanograms/kg/min
Monitoring	• Ensure adequate monitoring • Pre and post ductal saturation	
Referral	Is this a baby who requires ECMO? Contact RHC, Glasgow Receiving Consultant AND ScotSTAR (as outlined below)	

Neonatal ECMO

Introduction

Extracorporeal Life Support (ECLS) has a long history which is interwoven with the development of cardiopulmonary bypass. In 1982 Bartlett published the initial ECMO experience with 45 neonates. ECMO had only been used when maximal conventional therapy was exhausted and the infants were considered moribund. With >50% survival in patients considered to have a 90% mortality interest in ECMO for newborn respiratory failure was high but even though these early results were promising the lack of a randomised control trial caused many medics to continue to doubt it's safety and efficacy.

Aim of Neonatal ECMO

Selecting patients for ECLS and timing of treatment are two difficult aspects. Due to the invasive nature of ECLS and its significant associated risks, ECLS has always been reserved to treat only those neonates in whom other less invasive and dangerous therapies have failed. It was originally reserved for patients whose predicted mortality was 80% (Cornish, 1995). However, as expertise has improved and other patients have been treated, selection criteria have broadened to include patients for whom the benefits of ECLS would outweigh its risks.

Indications

Babies must have a **reversible lung condition** to be eligible for ECMO. The most common indications are:

- Meconium Aspiration Syndrome
- Congenital Diaphragmatic Hernia
- Sepsis
- Persistent Pulmonary Hypertension (other causes)
- Respiratory Distress Syndrome
- Air Leak Syndrome

AND meet the following criteria:

Criteria for consideration of ECMO:

- Weight > 2000g and >34 weeks' gestation. Smaller and more immature babies requiring maximal conventional support may be eligible as we have experience of cannulating down to 1800g.
- Not more than 7 days of high pressure ventilation
- Less than 28 days' old
- All congenital diaphragmatic hernia
- Unresponsive to maximal conventional management
- OI approaching 25 or PaCO₂ >90 mmHg

Contraindication to ECMO:

- Congenital/acquired CNS abnormality (including grade III-IV intraventricular haemorrhage).
- Irreversible cardiopulmonary disease
- Period of asystole (outside post-delivery period)
- Major chromosomal/ congenital abnormalities. However, some chromosomal defects are now not a contraindication (e.g. Down's Syndrome).

Further Reading

Causes of Respiratory Failure in the Term Infant

Persistent Pulmonary Hypertension of the Newborn (PPHN)

The term “PPHN” refers to a clinical syndrome characterised by hypoxic respiratory failure and associated systemic cyanosis and hypotension occurring from the time of birth. PPHN is not a single entity, but may be due to a number of possible causes. At a pathophysiological level PPHN is associated with persistence of fetal circulation at birth and ongoing elevation of pulmonary artery pressures (PAP).

Pressure in the pulmonary circulation is in simple terms the product of flow (pulmonary blood flow, PBF) and resistance (pulmonary vascular resistance, PVR). PVR is determined by the net resistance of the pulmonary arteries to the left atrium. Pulmonary hypertension (PH) refers to elevation of pulmonary artery pressure (PAP).

$$PA_{\text{Pressure}} = PB_{\text{Flow}} \times PV_{\text{Resistance}}$$

PPHN occurs in as many as 2-6/1000 live births and is a frequent a complicating factor of term parenchymal lung disease.¹

PPHN is most commonly associated with increased PVR due to three potentially co-existent mechanisms:

- Maladaptation of the pulmonary vasculature (abnormal parenchyma with increased PVR) leading to acute pulmonary vasoconstriction due to acute perinatal events, such as:
- Alveolar hypoxia secondary to parenchymal lung disease, such as respiratory distress syndrome (RDS) or pneumonia
- Hypoventilation resulting from asphyxia or other neurologic conditions
- Hypothermia
- Hypoglycaemia
- Sepsis

The second cause, **idiopathic PPHN** due to **maldevelopment of pulmonary vasculature** (normal parenchyma and increased PVR) which is associated with a normal chest radiograph and no parenchymal lung disease. Newborns with idiopathic PPHN present with pure vascular disease. This syndrome typically results from:

- Abnormally remodelled or hypoplastic pulmonary arterial bed e.g. secondary to chronic stress
- Alveolar Capillary Dysplasia with Malaligned Pulmonary Veins (ACD-MPV)
- Maternal medications including NSAIDs, SSRIs
- CDH
- Pulmonary hypoplasia of another cause.

The third category is due to **pulmonary venous congestion (post-capillary PH)** due to:

1. **Left ventricular dysfunction:** This may be particularly important in disease states that result in abnormal LV performance (infants with hypoxic ischemic encephalopathy [HIE], and infants born following twin to- twin transfusion [TTTS])
2. **Increased pulmonary blood flow.** A rare cause of PPHN with or without elevation of

PVR. This may be seen with large extra-cardiac shunts such as intra-cranial arterio-venous malformations (Vein of Galen Aneurysmal Malformation, VGAM)

Congenital Diaphragmatic Hernia (CDH)

The assessment and management of infants with CDH is outwith the scope of this guidance and it has been agreed that infants either with an antenatal or postnatal diagnosis of CDH should be managed as per the well-established pathway already in place:
<https://www.nn.nhs.scot/scans/professionals/sdhcn-guidelines/>

Meconium Aspiration Syndrome (MAS)

The passage of meconium occurs antenatally due to acute or chronic hypoxia. In utero, hypoxia can cause the fetus to gasp, which in turn can lead to aspiration of meconium. The majority of infants with meconium aspiration have symptoms of mild respiratory distress, however it can cause severe respiratory distress, hypoxaemia and associated pulmonary hypertension.

There is no evidence that routine suctioning at delivery prevents meconium aspiration as it almost always occurs antenatally.

Meconium aspiration causes lung pathology in two ways:

- emphysema with partial obstruction, caused by air entering the alveoli which is unable to leave on expiration due to blockage by meconium particles. This leads to gas trapping and areas of alveolar over distension, which in turn can cause air leak.
- atelectasis as a result of total obstruction of the airway by meconium, causing ventilation-perfusion mismatch.

The presence of meconium in the airways also causes surfactant dysfunction and chemical pneumonitis. Surfactant dysfunction causes further atelectasis and chemical pneumonitis causes cytokine release and inflammation of the lung parenchyma.

The effects of MAS can lead to gross ventilation-perfusion (V/Q) mismatch and many of these infants already have PPHN as a result of in-utero compromise. Postnatally, further hypoxaemia and hypercapnia contribute to pulmonary vasoconstriction which further increases pulmonary vascular resistance. The high pulmonary pressures cause right to left shunting through the foramen ovale and ductus arteriosus, which lowers the saturations further.

Sepsis

The incidence of culture-proven sepsis is approximately 2 per 1000 live births. The mortality rate in neonatal sepsis may be as high as 50% for infants who are not treated. Infection is a major cause of fatality during the first month of life, contributing to 13-15% of all neonatal deaths. Pneumonia is more associated with early onset sepsis, whereas meningitis and bacteraemia are more commonly seen in late onset sepsis.

Respiratory Distress Syndrome (RDS)

Respiratory Distress Syndrome (RDS) occurs most commonly in premature infants and is due to deficiency in surfactant leading to alveolar collapse, atelectasis and subsequent respiratory failure due to ventilation-perfusion mismatch. Although more common in premature infants, it does occur in term infants. Term infants can have RDS when they are the infant of a diabetic

mother or are delivered by elective c-section before 39 weeks. Surfactant can also be inactivated as described above, by meconium or in other circumstances such as infection, presence of blood or asphyxia. Steroids are administered to mothers antenatally, ideally 12-48 hours prior to an expected delivery at high risk of surfactant deficiency to stimulate surfactant production.

In term and near-term infants, the increased pulmonary vascular resistance which results from surfactant deficiency and dysfunction causes right to left shunting across the foramen ovale and/or ductus arteriosus, which as described above can lead to PPHN. Several diagnoses can co-exist and worsen RDS. These include:


- Pneumonia, often secondary to group B beta-haemolytic streptococci.
- Metabolic problems (e.g., hypothermia, hypoglycaemia).
- Haematological problems (e.g., anaemia)
- Retained lung fluid (so called transient tachypnoea of the newborn (TTN))
- Aspiration syndromes which may result from aspiration of amniotic fluid, blood, or meconium.
- Pulmonary air leaks (e.g., pneumothorax, interstitial emphysema, pneumomediastinum, pneumopericardium)
- Congenital anomalies (e.g., congenital diaphragmatic hernia) resulting in pulmonary hypoplasia.

Phenotypes of Acute Pulmonary Hypertension

Increased pulmonary artery pressure is variably associated with (Figure 1):

- Right to left shunting between atria and across the PDA leading to hypoxia / cyanosis
- Right ventricular (RV) dilatation and dysfunction leading to reduced pulmonary blood flow
- Left ventricular dysfunction, which may be primary or secondary to RV dysfunction, leading to systemic hypotension

Figure 1) Pathophysiological models of PPHN Siefkes HM, Lakshminrusimha S. *Arch Dis Child Fetal Neonatal Ed* 2021



Pathophysiology of hypoxic respiratory failure

Table 1) Pulmonary hypertension phenotypes: pathophysiology and echocardiography features *SM Boyd et al. Clin Perinatol 51 (2024) 45–76. Accessed June 2026 via [Targeted Neonatal Echocardiography in the Management of Neonatal Pulmonary Hypertension - Clinics in Perinatology](#)*

PH Phenotype	Pathophysiology	Echocardiography Features
Acute PH		
Arterial (classic)	Hypoxic pulmonary vasoconstriction and V/Q mismatch	Dilated (possibly hypertrophied) RV, septal flattening in systole, predominantly R→L PDA and atrial shunts, ↑PVRi (RVET:PAAT) > 4 and/or PA Doppler notching, ↓ PV Vmax < 0.25 m/s, ↓ LVO
Flow mediated (eg, VGAM)	High volume of blood in a circuit with limited capacitance, endothelial dysfunction, and oxidative stress	Dilated RV and/or LV, discordant ventricular outputs with either ↑RVO, ↑LVO or both, septal flattening in diastole if ASD/VSD
Left heart dysfunction (postcapillary)	Poor LV compliance and high LVEDP resulting in impaired flow through pulmonary circuit	Dilated LA and/or LV, LV systolic and diastolic dysfunction [↓MVE, ↑IVRT or E:e', ↓ PV S/D ratio, PV a wave], MR and/or AI, ↓LVO
Chronic PH		
Arterial (classic) for example, associated with BPD	Pulmonary vascular remodeling, impaired angiogenesis, and alveolar hypoxia/hyperoxia	Dilated and hypertrophied RV, septal flattening in systole, predominantly R→L PDA and atrial shunts, ↑↑PVRi (RVET:PAAT) > 4 and/or PA Doppler notching, ↓ LVO
Flow mediated (eg, ASD shunt)	High volume of blood in a circuit with limited capacitance, interstitial edema, and pulmonary vascular remodeling	Dilated RV or LV, discordant ventricular outputs with either ↑RVO, ↑LVO or both, septal flattening in diastole if ASD/VSD
Systemic hypertension	High LV afterload causing ↑LVEDP, LA hypertension, and pulmonary venous congestion	Dilated LA, LV, LV diastolic dysfunction [↓MVE, ↑IVRT or E:e', ↓ PV S/D ratio, PV a wave], MR, and/or AI

Abbreviations: AI, aortic insufficiency; ASD, atrial septal defect; BPD, bronchopulmonary dysplasia; D, d wave; IVRT, isovolumetric relaxation time; LA, left atrium; LV, left ventricle; LVEDP, left ventricular end-diastolic pressure; LVO, left ventricular output; MR, mitral regurgitation; MVE, mitral valve early wave; PA, pulmonary artery; PAAT, pulmonary artery acceleration time; PDA, patent ductus arteriosus; PV, pulmonary vein; PVRi, pulmonary vascular resistance index; R-L, right-to-left; RV, right ventricle; RVET, right ventricular ejection time; RVO, right ventricular output; S, s wave; V/Q, ventilation/perfusion; VGAM, vein of Galen malformation; VSD, ventricular septal defect.

Clinical Assessment and Monitoring

Clinical assessment of Pulmonary Hypertension

In an infant with suspected PH and HRF the initial evaluation should include a thorough history, physical examination, and physiological monitoring (ECG, blood pressure, pre and post ductal oxygen saturation) and initial investigations (arterial blood gas, chest X-ray) to assess the underlying condition and severity of PH.

Differentiating cyanotic congenital heart disease (CHD) from PH is of paramount importance, but can be challenging. Until a definitive echocardiographic diagnosis can be made, PGE1 should be used to maintain ductal patency in the critically unwell newborn.

The clinical significance of PH is therefore based on combined assessment of (Table 2):

- I. Oxygenation
- II. Pulmonary artery pressure
- III. Cardiac function (in right and left ventricles)

Direct measurement of pulmonary artery pressure (PAP) and cardiac function using “gold standard” techniques of cardiac catheterisation is not safe or practical in newborns. Instead, echocardiography is the clinical standard.

PAP can be estimated by echo using two principal techniques:

- a) Peak velocity of tricuspid regurgitation jet (TR_{max}): PAP is estimated from the TR_{max} using a modified Bernoulli equation ($PAP = 4 \times TR_{max}^2$). However, TR may not always be present, even in severe PH, and the technique is prone to measurement error.
- b) Direction and velocity of flow in patent ductus arteriosus (PDA): Flow through an unrestricted PDA is determined by pressure gradient differences between the pulmonary artery and aorta. Bidirectional, or right-to-left flow patterns indicate PAP equal or greater than systemic aortic pressure.

Additional echocardiographic techniques, including time to peak velocity in the pulmonary artery (PAAT) and septal position may also be used to assess PAP/PVR. Tricuspid annular plane systolic excursion (TAPSE) and Tissue Doppler Imaging (TDI) could be measured to assess systolic ventricular function.

Clinical assessment of PH in the newborn infant

Oxygenation	Pulmonary artery pressure	Cardiac function
Arterial oxygen saturations, SpO_2	Pre-post ductal oxygen saturation differences	Invasive systemic blood pressure (including pulse pressure)
Arterial PaO_2	Echocardiographic assessment:	Echocardiographic assessment:
Plasma lactate	• Tricuspid regurgitation velocity	• “Eyeballing” from 2d loops
Venous oxygen saturation ($SpVO_2$)	• PDA shunting pattern • Shunting pattern through PFO • Time to peak velocity in pulmonary artery • Septal shape	• Quantitative measures of cardiac function in right and left ventricle

Table 2) Clinical assessment of PH in newborn infant. Montasser M & Patel N. Paediatrics & Child Health, 2021.

Advanced Monitoring of Hypoxic Respiratory Failure

It is important to continuously monitor response to treatment. There are different parameters that could be used to monitor oxygenation:

1. **Oxygen saturation histograms** can be extrapolated from bedside monitors. Target range should be equal or above 95% and avoid hypoxia (<85%) and hyperoxia (>98%) for prolonged periods.

2. **Alveolar-arterial (A-a) gradient:**

A/a gradient = $P_{A}O_2 - P_{a}O_2$. Normally 5 –10, if no impediment to diffusion

Alveolar $P_{A}O_2$ can be calculated using alveolar gas equation as follows:

$$\text{Alveolar Partial pressure of O}_2 (P_{A}O_2) = [F_{i}O_2 \times (760 - 47)] - (P_{a}CO_2 / 1)$$

760 is atmospheric pressure at sea level, 47 is when assuming 100% humidity of alveoli, 1 is the respiratory quotient in neonates

3. **Oxygenation Index (OI):**

$$OI = (MAP \times F_{i}O_2 \times 100) / P_{a}O_2 \text{ in mmHg. (1 Kpa = 7.5 mmHg)}$$

MAP= mean airway pressure

4. **Oxygen Saturation Index (OSI):**

$$OSI = (MAP \times F_{i}O_2 \times 100) / SpO_2$$

5. **Brain Oxygen Saturation** by NIRS (near infrared spectroscopy) monitor if available.

Degree of severity of HRF could be assessed by the following table:

Management

Table 3) Management of Pulmonary Hypertension in HRF

MONITORING OXYGENATION – ALWAYS LOOK AT THE TREND

Parameters	Target	Moderate	Severe
Oxygen saturation histograms	100% within the target	<5% hypoxemia <10% hyperoxia	>5% hypoxemia >10% hyperoxia
A–a gradient	<20	20–100	>100
Oxygenation index	<5	10–15	>15
Oxygen saturation index	<2.5	5–7.5	>7.5
Saturation : $F_{i}O_2$ ratio (SFR)	>350	180–350	<180
V:Q Ratio	>0.75	0.5–0.75	<0.5
R–L shunt	<10%	10–20	>20%
Brain oxygen saturation	60–80%	<60%	<50%

Table 4) Physiologic Goals & Therapeutic Recommendations SM Boyd et al. Clin Perinatol 51 (2024) 45–76. Accessed June 2026 via [Targeted Neonatal Echocardiography in the Management of Neonatal Pulmonary Hypertension - Clinics in Perinatology](#)

PH Phenotype	Physiologic Goals	Suggested Treatment Approach
Acute PH		
Arterial (classic)	Reduce PVR Augment RV performance Support SAP and maintain coronary perfusion pressure	Optimize lung recruitment and supportive care Offload RV with pulmonary vasodilators Augment RV function with inotropes if required Support SAP with vasoconstrictors which do not ↑PVR Consider maintaining ductal patency with PGE
Flow mediated	Shunt control Maintain ↑PVR	Specific shunt management Avoid selective pulmonary vasodilators Consider permissive hypercapnia (pCO ₂ 50–60 mmHg, pH > 7.25) Avoid hyperoxia (goal preductal SpO ₂ 91%–95%* and preductal pCO ₂ 50–80 mm Hg ¹³⁸) *higher SpO ₂ may be needed if undergoing TH
Left heart dysfunction (postcapillary)	LV afterload reduction Positive inotropy Maintain ↑PVR Maintain R→L ductal shunt if ↓SBF	LV afterload reduction if SAP adequate, for example, inodilator Positive inotropy Avoid selective pulmonary vasodilators Diuretics for pulmonary edema
Chronic PH		
Arterial (classic) for example, associated with BPD	Reduce PVR	Optimize lung recruitment and supportive care Offload RV with pulmonary vasodilators Consider diuretics if RV dilation Avoid hypoxia and hyperoxia (target oxygen saturations 92%–95% ¹⁰⁶)
Flow mediated	Shunt control Maintain ↑PVR	Specific shunt management (reduction in or closure of L-R shunt if feasible and appropriate) Avoid selective pulmonary vasodilators Diuretics for ASD/VSD Positive end expiratory pressure
Systemic hypertension	LV afterload reduction Maintain ↑PVR	Antihypertensive therapy role for ACE inhibitors/ARB Avoid pulmonary vasodilators


Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker; ASD, atrial septal defect; L, left; PGE, prostaglandin E, PH; pulmonary hypertension, PVR; pulmonary vascular resistance, R; right, RV; right ventricle, SAP; systolic arterial pressure, SBF; systemic blood flow, TH; therapeutic hypothermia, VSD; ventricular septal defect.

Pulmonary vasodilator therapies

Use of inhaled nitric oxide is associated with improved oxygenation and outcome (death/need for ECMO) in term infants with hypoxic respiratory failure (ref). Second line pulmonary vasodilators (e.g. sildenafil) should be reserved for use in experienced centres.

Pulmonary vasodilators (e.g. iNO) are contraindicated in specific situations as illustrated in Figure 2.

Figure 2) Pathophysiological models of PPHN MW Cookson & JP. Kinsella. *Clin Perinatol* 51 (2024) 45–76. Accessed June 2026 via [Inhaled Nitric Oxide in Neonatal Pulmonary Hypertension - Clinics in Perinatology](#)



Contraindications for iNO therapy in HRF. Congenital methemoglobinemia or MetHb reductase deficiency can be exacerbated by iNO therapy worsening hypoxemia. LV dysfunction and pulmonary venous hypertension are worsened by iNO due to pulmonary edema. Ductal-dependent systemic circulation as seen in hypoplastic left heart syndrome (HLHS), critical aortic stenosis (AS), or coarctation of the aorta (Co-A) maintain their systemic circulation through a right-to-left shunt across the patent ductus arteriosus (PDA). Reduced pulmonary arterial pressure by iNO abolishes this shunt and causes systemic hypoperfusion.

Management of Systemic Hypotension in HRF

Mechanisms of hypotension and treatment approaches are summarised in Table 5.

Table 5) Mechanisms of systemic hypotension in PPHN/HRF

Mechanism of systemic hypotension		Clinical findings	Therapeutic principle	Therapy
↓ LV function (common)		↓ pulse pressure Echo evidence	↑ cardiac function	Adrenaline (0.03-0.05 mcg/kg/min) OR Dobutamine 5-10 mic/kg/min *Consider Milrinone in level 3 units
↓ LV filling / Preload	↓ PBF	↓ pulse pressure.	↓ PVR	Pulmonary vasodilator therapies
	Hypovolaemia		↑	Volume / RBC transfusion
Systemic vasodilatation		↓ diastolic pressure	Vasoconstriction	Low dose noradrenaline or vasopressin. Caution in LV dysfunction.

**Milrinone may also be considered to treat cardiac dysfunction in centres with experience. Milrinone is a systemic (and pulmonary) vasodilator so should only be used with caution if there is pre-existing hypotension.*

Important considerations for Milrinone:

1. Milrinone should be used in tertiary centres preferably after formal echo assessment by cardiologist or neonatologist experienced in echocardiography and haemodynamics.
2. **Do not** give Milrinone bolus to avoid systemic hypotension.
3. Start at 0.3 mic/kg/min and gradually (every 4-6 hrs) increase to 0.5 mic/kg then finally to 0.7 mic/kg if no side effect of systemic hypotension. Milrinone should also be weaned slowly over 24-48 hrs.
4. Milrinone should be used with caution **or better avoided** in HIE infants due to significant decrease of its metabolism (renal) and it's build up and accumulation in the body leading to much more side effects. In these infants never give Milrinone bolus.
5. Dopamine and pulmonary hypertension: Due to its effect on increasing PVR, dopamine can contribute or worsen hypoxemic respiratory failure and PH. By inducing pulmonary vasoconstriction, dopamine may increase right ventricular (RV) afterload and contribute to RV dysfunction. This can increase RV end-diastolic pressure and the volume of right-to-left shunting at the atrial level. Decreased pulmonary blood flow is associated with decreased pulmonary venous return, LV preload, and lower LV output, ultimately impairing tissue blood flow and oxygen delivery. Therefore, Dopamine should be avoided in the setting of acute pulmonary hypertension and HFR.

Special Considerations in Management of Hypotension and Cardiac Function in PPHN:

1. **LV dysfunction:** LV dysfunction is common in infants with a clinical presentation of “PPHN”, and may be secondary to acidosis and hypoxia during the transitional process. LV dysfunction contributes to increased PAp (and hence hypoxic shunting) and to systemic hypotension in PPHN. Inotropic therapy should be used to support cardiac function, and ECMO considered in severe cases. LV dysfunction is a transitional phenomenon and typically improves with supportive therapy over the first days of life.

Adrenaline in lower dose (0.03-0.1 mcg/kg/min or dobutamine (5-10 mcg/kg/min) are suitable first line agents. Milrinone improves systolic (inotropic) and diastolic (lusitropic) function and may be used in experienced centres.

Pulmonary vasodilators and systemic vasoconstrictors **should be used with caution in LV dysfunction** as they may worsen LV function by increasing preload and afterload respectively.

2. **Maintaining ductal patency:** Prostaglandin infusion may be used to maintain ductal patency as a “blow-off” valve for the pressure loaded RV. This should be guided by echocardiographic evidence of 1) Supra-systemic PA pressure (i.e. PAP>Systemic BP), Dilated/dysfunctional RV, and closing PDA.
3. **Volume administration:** Fluid boluses should only be administered if there is evidence of hypovolaemia, such as low central venous pressure or diastolic pressure, documented excessive losses or concerns for increased insensible losses.
4. **Infants born to mothers with diabetes** may have hypertrophic cardiomyopathy. Catecholamine infusions may cause increased inotropy and/or chronotropy and exacerbate left ventricular outflow obstruction. Milrinone in conjunction with β -blockade, may provide improved cardiac output and oxygenation due to its inotropic effect without chronotropy, its ability to relax the heart muscle in diastole (lusitropy) and vasodilatory properties.

References

- Mathew B and Lakshminrusimha S. Persistent Pulmonary Hypertension in the Newborn. Children 2017, 4, 63.
- Satyan Lakshminrusimha. The Pulmonary Circulation in Neonatal Respiratory Failure. Clin Perinatol 39 (2012) 655–683.
- Amish Jain and Patrick J. McNamara. Persistent pulmonary hypertension of the newborn: Advances in diagnosis and treatment. Seminars in Fetal & Neonatal Medicine 20 (2015) 262e271.
- Mahmoud Montasser and Neil Patel. Pulmonary hypertension in newborn infants: pathophysiology, clinical assessment and management. Paediatrics & Child Health, volume 31, issue1. January 2021.
- SM Boyd et al. Targeted Neonatal Echocardiography in the Management of Neonatal Pulmonary Hypertension. Clin Perinatol 51, 2024.
- MW Cookson and JP. Kinsella. Inhaled Nitric Oxide in Neonatal Pulmonary Hypertension. Clin Perinatol 51, 2024.
- Heather M Siefkes and Satyan Lakshminrusimha. Management of systemic hypotension in term infants with persistent pulmonary hypertension of the newborn: an illustrated review. Arch Dis Child Fetal Neonatal Ed 2021;0: F1–F10.
- Ruoss J, et al. Updates on Management for Acute and Chronic Phenotypes of Neonatal Pulmonary Hypertension. Clin Perinatol 47 (2020) 593–615.
- Audrey Hebert et al. Physiology-guided vasoactive therapy in neonates: rethinking dopamine as first-line. J Perinatol . 2025 Oct;45(10)

Development

Lead Authors

Dr Andrew MacLaren, Consultant Neonatologist, NHS Greater Glasgow & Clyde, RHC & ScotSTAR (Group Chairperson).

Dr Mahmoud Montasser, Consultant Neonatologist, NHS Lanarkshire, UHW & ScotSTAR.

Dr Jonathan Coutts, Consultant Neonatologist, NHS Greater Glasgow & Clyde, RHC.

Dr Maria Duggan, Neonatal GRID Trainee, North of Scotland.

Other Members of the Group

Dr Lesley Jackson, Consultant Neonatologist, NHS Greater Glasgow & Clyde, RHC.

Dr Andrew Powls, Consultant Neonatologist, NHS Greater Glasgow & Clyde, PRM.

Dr Saulius Satas, Consultant Neonatologist, NHS Grampian, AMH.

Dr Philline Van der Heide, Consultant Paediatrician, NHS Highland, Raigmore.

Other Professionals Consulted

Mr James Andrews, Consultant Surgeon, NHS Greater Glasgow & Clyde, RHC.

Peter Mulholland, Neonatal Pharmacist, NHS Greater Glasgow & Clyde, RHC.

Dr Neil Patel, Consultant Neonatologist, NHS Greater Glasgow & Clyde, RHC.

Dr Judith Simpson, Consultant Neonatologist, NHS Greater Glasgow & Clyde, RHC.

Mr Gregor Walker, Consultant Surgeon, NHS Greater Glasgow & Clyde, RHC.

Appendix 1

Drugs used in the management of infants with hypoxic respiratory failure

Adapted from Siefkes HM, Lakshminrusimha S. Arch Dis Child Fetal Neonatal Ed 2021;0:F1–F10.

See more information and full monograph for drugs listed below at:

<https://www.perinatalnetwork.nhs.scot/professionals/guidance/local-regional-drug-monographs/>

Goals of Treatment of PH:

The ultimate goal is to achieve adequate pulmonary blood flow (PBF) and systemic blood flow (SBF) by:

1. Increasing systemic vascular resistance (SVR) to an adequate level (with caution in cases with severe LV dysfunction as it might worsen the condition).
2. Decrease pulmonary vascular resistance (PVR) and pulmonary artery pressure (PAP) by using pulmonary vasodilators.
3. Optimize heart function (inotropes/lusitropes) and avoid excessive myocardial oxygen consumption (good analgesia/sedation and avoid excessive tachycardia).
4. Maintaining ductal patency in supra-systemic pulmonary hypertension with biventricular dysfunction as duct will work as a 'pop-off' valve for the right ventricle and more importantly will provide systemic blood flow by right to left shunting. In these conditions, avoid reversing the direction of shunt flow before supporting the biventricular dysfunction (e.g. with Milrinone).

Vasoactive Drugs

Note: Doses advised are to avoid side effects when using the higher end of the dose range. Drug dosages are only guaranteed to be correct at the date of publication. Clinicians must verify against e.g. BNF for Children or current monographs in the event that these should change in the period between publication and review.

Drugs	Receptors	SVR	PVR	SV	HR	Contractility	BP (MAP)	Dosage	Effects	Pearls (When to consider)
Noradrenaline	α_1 α_2 β_1	↑↑↑	↑	↑	↑	No effect	↑↑	0.02-0.2 mic/kg/min Start: 0.05 mic/kg/min	↑SVR & PVR ↑MAP ↓PAP	Start when HR>160 Adr< β_1 activity<Noradr Good for septic shock
Adrenaline	α_1 α_2 β_1 β_2	↑↑↑	↑	↑	↑↑↑	↑	↑↑	0.02-0.2 mic/kg/min Start: 0.05 mic/kg/min	↑SVR, ↑MAP ↑Contractility	<0.1 (β_1 β_2) -↑ function >0.1 (β_1 β_2 α_1 α_2) - ↑ MAP
Vasopressin	V_1 V_2	↑↑↑	↓↓	↑	No effect	No effect	↑↑	0.1-1.2 milliunit/kg/min Start: 0.1 milliunit/kg/min	↑SVR, ↑MAP ↓PVR	Increase Preload Possible 1 st line ↑SVR & ↓PVR Monitor for Hypo Na Avoid w/LV Dysfunction
Hydrocortisone		↑↑↑	No effect	No effect	↑	No effect	↑↑	1mg/kg/dose q 8 hr	↑SVR, ↑MAP	Delayed response for 4-8 h Add with 2 nd line agent
Milrinone	PDE III Inhibitor	↓↓	↓↓	↑↑	↑	↑	↓	0.2- 0.75 mic/kg/min Start: 0.33 mic/kg/min	↑Contractility ↓SVR & PVR ↓MAP	Not 1 st line Use w/ severe Heat dysf & stable BP ↓PAP & will ↓SVR
Dopamine	α_1 β_1 β_2 D	↑↑	↑↑↑	↑	↑↑↑	↑	↑↑	2-10 mic/kg/min Start: 5 mic/kg/min	↑SVR & ↑↑↑PVR ↑MAP ↑Contractility	<2 : D ↑UOP 2-6: β_1 D ↑Function >6: α_1 β_1 D ↑SVR causes ↑↑↑PVR & ↑↑HR
Dobutamine	α_1 β_1 Weak β_2	No effect	No effect	↑↑	↑↑	↑	↓	2-10 mic/kg/min Start: 5 mic/kg/min	↑Contractility ↓SVR (high doses)	Cardiac dysfunction Can cause ↓ SVR

α_1 α_2	Peripheral Vasoconstriction
β_1	↑COP (Chronotropy & Inotropy)
β_2	Vasodilatation

Dop	Renal vasodilatation, Increase contractility
V_1	Systemic vasoconstriction
V_2	Pulmonary vasodilatation

Drug	Cutoff Value → consider 2 nd agent
Adrenaline	0.1 microgram/kg/min
Noradrenaline	0.1 microgram/kg/min
Dopamine	7.5-10 microgram/kg/min

PPHN Goals: Adequate PBF & SBF
a) ↑SVR
b) ↓PVR & ↓PAP
c) Optimize Heart Fx

All content is available under the [Open Government Licence V3.0](#) except for graphic assets and where otherwise stated.